Cue Operating Income from 2010 to 2026

CUE Stock

USD 0.28 0.01 3.45%

Cue Biopharma's Operating Income is decreasing over the years with slightly volatile fluctuation. Operating Income is expected to dwindle to about -39.2 M. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Cue Biopharma generates from its operations. View All Fundamentals

Operating Income

First Reported

2015-12-31

Previous Quarter

-8.6 M

Current Value

-7.5 M

Quarterly Volatility

3.9 M

Yuan Drop

Covid

Interest Hikes

Check Cue Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cue Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 1.2 M or Selling General Administrative of 12.1 M, as well as many indicators such as Price To Sales Ratio of 7.22, Dividend Yield of 0.0 or PTB Ratio of 6.55. Cue financial statements analysis is a perfect complement when working with Cue Biopharma Valuation or Volatility modules.

Build AI portfolio with Cue Stock

Check out the analysis of Cue Biopharma Correlation against competitors.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

Analyzing Cue Biopharma's Operating Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Income has evolved provides context for assessing Cue Biopharma's current valuation and future prospects.

Latest Cue Biopharma's Operating Income Growth Pattern

Below is the plot of the Operating Income of Cue Biopharma over the last few years. Operating Income is the amount of profit realized from Cue Biopharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cue Biopharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Cue Biopharma's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cue Biopharma's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Cue Operating Income Regression Statistics

	Arithmetic Mean	(25,301,553)
	Coefficient Of Variation	(81.09)
	Mean Deviation	18,817,393
	Median	(36,769,000)
	Standard Deviation	20,516,138
	Sample Variance	420.9T
	Range	51.3M
	R-Value	(0.88)
	Mean Square Error	103.7T
	R-Squared	0.77
	Slope	(3,562,811)
	Total Sum of Squares	6734.6T

Cue Operating Income History

	2026	-39.2 M
	2025	-37.4 M
	2024	-41.5 M
	2023	-52.1 M
	2022	-53.2 M
	2021	-43.7 M
	2020	-45 M

Other Fundumenentals of Cue Biopharma

Non Operating Income Net Other

Cue Biopharma Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Deferred Long Term Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Intangible Assets	Capital Surpluse	Capital Stock	Long Term Debt	Long Term Debt Total
Total Assets		0.94	0.86	-0.86	-0.58	0.68	0.55	0.86	0.77	1.0	0.51	0.53	0.61	0.33	0.04	-0.16	-0.04	0.5	-0.76	0.57	0.31	-0.1	-0.13
Total Stockholder Equity	0.94		0.77	-0.95	-0.35	0.53	0.56	0.72	0.72	0.95	0.25	0.48	0.67	0.28	0.28	-0.35	0.21	0.31	-0.58	0.39	0.12	0.14	0.15
Net Tangible Assets	0.86	0.77		-0.71	-0.82	0.89	0.33	0.9	0.85	0.85	0.78	0.43	0.4	0.33	-0.31	0.32	-0.41	0.8	-0.84	0.82	0.7	-0.51	-0.25
Net Debt	-0.86	-0.95	-0.71		0.24	-0.44	-0.31	-0.58	-0.67	-0.88	-0.16	-0.4	-0.64	-0.39	-0.3	0.31	-0.25	-0.22	0.43	-0.27	-0.02	-0.14	-0.19
Retained Earnings	-0.58	-0.35	-0.82	0.24		-0.92	-0.17	-0.85	-0.6	-0.53	-0.95	-0.23	-0.06	-0.3	0.61	-0.63	0.71	-0.95	0.85	-0.96	-0.91	0.82	0.47
Accounts Payable	0.68	0.53	0.89	-0.44	-0.92		0.28	0.89	0.78	0.65	0.84	0.2	0.16	0.36	-0.49	0.5	-0.58	0.92	-0.87	0.91	0.81	-0.69	-0.28
Short Term Investments	0.55	0.56	0.33	-0.31	-0.17	0.28		0.53	0.47	0.55	0.11	0.5	0.57	-0.39	0.12	-0.43	0.12	0.11	-0.52	0.18	0.03	0.25	0.14
Total Liab	0.86	0.72	0.9	-0.58	-0.85	0.89	0.53		0.73	0.83	0.74	0.46	0.48	0.28	-0.26	0.21	-0.36	0.8	-0.93	0.85	0.66	-0.47	-0.21
Deferred Long Term Liab	0.77	0.72	0.85	-0.67	-0.6	0.78	0.47	0.73		0.77	0.58	0.5	0.32	0.18	-0.38	0.15	-0.4	0.62	-0.74	0.53	0.46	-0.33	-0.13
Total Current Assets	1.0	0.95	0.85	-0.88	-0.53	0.65	0.55	0.83	0.77		0.47	0.52	0.62	0.3	0.06	-0.19	-0.01	0.45	-0.71	0.52	0.26	-0.06	-0.12
Common Stock	0.51	0.25	0.78	-0.16	-0.95	0.84	0.11	0.74	0.58	0.47		0.26	-0.04	0.22	-0.74	0.69	-0.82	0.9	-0.79	0.88	0.9	-0.85	-0.68
Property Plant Equipment	0.53	0.48	0.43	-0.4	-0.23	0.2	0.5	0.46	0.5	0.52	0.26		0.5	0.05	-0.21	-0.17	-0.2	0.25	-0.56	0.14	0.08	-0.01	-0.13
Current Deferred Revenue	0.61	0.67	0.4	-0.64	-0.06	0.16	0.57	0.48	0.32	0.62	-0.04	0.5		0.0	0.37	-0.42	0.34	0.03	-0.41	0.11	-0.1	0.25	0.26
Net Receivables	0.33	0.28	0.33	-0.39	-0.3	0.36	-0.39	0.28	0.18	0.3	0.22	0.05	0.0		-0.07	0.07	-0.13	0.42	-0.32	0.3	0.14	-0.18	-0.13
Net Invested Capital	0.04	0.28	-0.31	-0.3	0.61	-0.49	0.12	-0.26	-0.38	0.06	-0.74	-0.21	0.37	-0.07		-0.77	0.99	-0.66	0.48	-0.44	-0.66	0.82	0.65
Short Long Term Debt	-0.16	-0.35	0.32	0.31	-0.63	0.5	-0.43	0.21	0.15	-0.19	0.69	-0.17	-0.42	0.07	-0.77		-0.81	0.66	-0.26	0.6	0.82	-0.95	-0.49
Net Working Capital	-0.04	0.21	-0.41	-0.25	0.71	-0.58	0.12	-0.36	-0.4	-0.01	-0.82	-0.2	0.34	-0.13	0.99	-0.81		-0.74	0.55	-0.56	-0.75	0.88	0.67
Short Term Debt	0.5	0.31	0.8	-0.22	-0.95	0.92	0.11	0.8	0.62	0.45	0.9	0.25	0.03	0.42	-0.66	0.66	-0.74		-0.86	0.94	0.92	-0.81	-0.41
Intangible Assets	-0.76	-0.58	-0.84	0.43	0.85	-0.87	-0.52	-0.93	-0.74	-0.71	-0.79	-0.56	-0.41	-0.32	0.48	-0.26	0.55	-0.86		-0.8	-0.68	0.52	0.33
Capital Surpluse	0.57	0.39	0.82	-0.27	-0.96	0.91	0.18	0.85	0.53	0.52	0.88	0.14	0.11	0.3	-0.44	0.6	-0.56	0.94	-0.8		0.93	-0.74	-0.34
Capital Stock	0.31	0.12	0.7	-0.02	-0.91	0.81	0.03	0.66	0.46	0.26	0.9	0.08	-0.1	0.14	-0.66	0.82	-0.75	0.92	-0.68	0.93		-0.88	-0.43
Long Term Debt	-0.1	0.14	-0.51	-0.14	0.82	-0.69	0.25	-0.47	-0.33	-0.06	-0.85	-0.01	0.25	-0.18	0.82	-0.95	0.88	-0.81	0.52	-0.74	-0.88		0.56
Long Term Debt Total	-0.13	0.15	-0.25	-0.19	0.47	-0.28	0.14	-0.21	-0.13	-0.12	-0.68	-0.13	0.26	-0.13	0.65	-0.49	0.67	-0.41	0.33	-0.34	-0.43	0.56

Click cells to compare fundamentals

About Cue Biopharma Financial Statements

Cue Biopharma stakeholders use historical fundamental indicators, such as Cue Biopharma's Operating Income, to determine how well the company is positioned to perform in the future. Although Cue Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cue Biopharma's assets and liabilities are reflected in the revenues and expenses on Cue Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cue Biopharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-37.4 M	-39.2 M
Non Operating Income Net Other	57.7 K	91.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill

When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:

How To Invest In Cue

Details

Is Cue Stock a good investment?

Details

What is Cue Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Cue Biopharma Correlation against competitors.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Will Biotechnology sector continue expanding? Could Cue diversify its offerings? Factors like these will boost the valuation of Cue Biopharma. Projected growth potential of Cue fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cue Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.

Earnings Share

(0.41)

Revenue Per Share

0.082

Quarterly Revenue Growth

(0.36)

Return On Assets

(0.62)

Return On Equity

(1.95)

Cue Biopharma's market price often diverges from its book value, the accounting figure shown on Cue's balance sheet. Smart investors calculate Cue Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cue Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.

It's important to distinguish between Cue Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cue Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Cue Operating Income from 2010 to 2026

Latest Cue Biopharma's Operating Income Growth Pattern

Cue Operating Income Regression Statistics

Cue Operating Income History

Other Fundumenentals of Cue Biopharma

Cue Biopharma Operating Income component correlations

About Cue Biopharma Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY